STELLAR-303
14 Sep 2023
Trial Summary
This is a multicenter, randomized, open-label, controlled Phase 3 trial of XL092 + atezolizumab vs regorafenib in subjects with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed after or are intolerant to standard-of-care (SOC) therapy.
Acronym:
STELLAR-303
ACTRN/NCT /ethics:
NCT05425940
Scientific title:
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Sponsor / Cooperative group:
Exelixis
Trial & Patient Characteristics
| Cancer Type | Colorectal Cancer |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | - |
| Anticipated Start Date | 2023-09-07 |
| Anticipated End Date | 2026-02-01 |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Pamela Cooper |
| Pamela.cooper@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Tim Price |
| Recruitment Status | Recruiting |